Skip to main content

Table 1 Clinical information of systemic sclerosis patients

From: Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis

No Sex Age range Disease duration, years Skin involvement ILD PAH GI involvement ANA Anti-centromere Anti-scl70
1 2 40–49 20 Limited Yes, NSIP No GERD 1:80, nucleolar Negative Negative
2 1 40–49 13 Diffuse Yes, NSIP + UIP Yes Recurrent paralytic ileus 1:1280, speckled Negative Negative
3 1 50–59 2 Diffuse Yes, UIP No GERD 1:1280, cytoplasmic Negative Positive
4 2 60–69 5 Diffuse Yes, NSIP No GERD 1:80, speckled Negative Negative
5 1 50–59 16 Diffuse No No GERD, scleroderma esophagus 1:640, speckled Negative Negative
  1. 1, Female; 2, Male; ILD, interstitial lung disease; PAH, pulmonary artery hypertension; ANA, antinuclear antibody; NSIP, nonspecific interstitial pneumonia; UIP, usual interstitial pneumonia; GERD, gastroesophageal reflux disease